Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring

Christian Siebel, Claudia Lanvers-Kaminsky, Gudrun Würthwein, Georg Hempel & Joachim Boos

The widespread clinical use of the cytostatic doxorubicin together with the induction of chronic cardiomyopathy necessitates the conduct of further pharmacokinetic trials. Novel analytical technologies suitable for point-of-care applications can facilitate drug level analyses but might be prone to interferences from structurally similar compounds. Besides the alcohol metabolite doxorubicinol, aglycone metabolites of doxorubicin might affect its determination in plasma. To evaluate their analytical relevance, a validated HPLC method for the quantification of doxorubicin, doxorubicinol and four aglycones was used. The degradation pattern of doxorubicin in plasma under long-term storage was analysed with respect to the formation of aglycone products. In addition, overall 50 clinical samples obtained within the EPOC-MS-001-Doxo trial were analysed. Substantial degradation of doxorubicin in plasma occurred within a storage period of one year, but this did not lead to the formation of aglycones. In clinical samples, 7-deoxydoxorubicinolone was the major aglycone detectable in 35/50 samples and a concentration range of 1.0–12.7 µg L⁻¹. If at all, the other aglycones were only determined in very low concentrations. Therefore, analytical interferences from aglycones seem to be unlikely with the exception of 7-deoxydoxorubicinolone whose concentration accounted for up to 65% of the doxorubicin concentration in the clinical samples analysed.
In vivo, DOX undergoes extensive metabolism. Doxorubicinol (DOXol) is the most common metabolite (Fig. 1) formed by two electron reduction of the C-13 carbonyl group to a hydroxyl group\(^{9,10}\). The reaction is catalysed by cytoplasmatic NADPH-dependent carbonyl and aldo–keto reductases in various tissues such as heart, liver, kidneys or red blood cells. DOXol is considerably less cytotoxic than the parent drug and is thought to contribute to its cardiotoxic effect\(^{10–12}\). Hydrolytic or reductive deglycosidation constitutes a minor metabolic pathway resulting in 7-hydroxy- or 7-deoxyaglycones (Fig. 1). Formation of the 7-hydroxyaglycones doxorubicinone and doxorubicinolone is catalysed by cytosolic NADPH-dependent glycosidases, whereas formation of the 7-deoxyaglycones 7-deoxydoxorubicinone and 7-deoxydoxorubicinolone is catalysed by microsomal oxidoreductases\(^{12}\). Aglycones do not exhibit cytotoxic activity but similar to DOXol they have been suggested to be cardiotoxic\(^{12,13}\). Subsequent metabolic steps involve O-demethylation, O-sulfation and O-β-glucuronidation\(^9\).

A number of studies investigated the pharmacokinetics of the aglycone metabolites. These studies provided inconclusive results regarding the type of aglycones that were detected in plasma of cancer patients as well as their expectable concentration range\(^{14–18}\). The purpose of the present analyses was to provide data from clinical plasma samples to allow for an accurate assessment of the potential relevance of aglycone metabolites for DOX drug monitoring. The formation of aglycone products in plasma samples under long term storage was also investigated.

**Methods**

**Reference substances and chemicals.** DOX was purchased from Sigma Aldrich Chemie GmbH (Munich, Germany). DOXol, doxorubicinone, doxorubicinolone, 7-deoxydoxorubicinone and 7-deoxydoxorubicinolone were purchased from Toronto Research Chemicals (Toronto, Canada). Stock solutions of the reference compounds were prepared in acetonitrile at a concentration of 20 mg L\(^{-1}\). The internal standard epirubicin was provided by Medac GmbH (Wedel, Germany) as a solution for infusion (2 g L\(^{-1}\)). Acetonitrile, chloroform, ethanol, formic acid, disodium hydrogen phosphate and phosphoric acid were purchased in HPLC grade from various suppliers. Leucocyte-depleted fresh frozen plasma was provided by the Department of Transfusion Medicine of the University Hospital Muenster. Left-over plasma samples were used that were fully anonymized beforehand.

**Chromatography.** For the determination of aglycones the HPLC method previously described by Kontny et al. was adapted\(^4\). Apart from DOX and DOXol the adapted HPLC method allows quantifying the aglycones doxorubicinone, doxorubicinolone, 7-deoxydoxorubicinone and 7-deoxydoxorubicinolone. Chromatographic separation of the aglycones was achieved by modifying the elution gradient of the original method. For sample preparation liquid–liquid extraction was performed with chloroform after adjustment of the pH to 8.5. To 100 µL of each sample 50 µL epirubicin was added as an internal standard. Overall 100 µL of phosphate buffer (pH 8.5) and 1000 µL of chloroform were added and the samples were mixed for 5 min on a rotation shaker. Subsequently, samples were centrifuged for 5 min at 4 °C and 20,000 g. The organic phase was transferred to a new polypropylene tube and evaporated to dryness under a stream of nitrogen at 35 °C. The residue was dissolved in 100 µL of a 0.1% formic acid in water: 0.1% formic acid in acetonitrile solution (75:25) and sonicated for 5 min before injection. An HPLC system equipped with a SIL-30AC autosampler, a RF-20Axs fluorescence detector and two LC-10ADvp pumps was used (Shimadzu, Duisburg, Germany). Analyses were run with a Purospher STAR RP-18 endcapped (5 µm) column (Merck KGaA, Darmstadt, Germany) and a mobile phase of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The gradient for elution was composed of: 25–30% B over 7 min, 30–35% B over 11 min, 35–55% B over 7 min, 55–95% B over 0.5 min for 5 min, 95–25% B over 0.5 min, 25% B for 5 min. Fluorescence of the analytes was excited at a wavelength of 488 nm and recorded at an emission wavelength of 555 nm. Separation of all analytes was achieved within 25 min.

The method was validated according to the European Medicines Agency (EMA) guideline on bioanalytical method validation\(^{19}\). In brief, the calibration range for DOX and DOXol was 2–1000 and 2–500µg L\(^{-1}\). The
aglycones could be determined in a concentration range from 1–100 µg L⁻¹. Within- and between-run accuracy and precision were determined at four concentrations in five replicates each. Accuracy for all analytes was 97.6–115% (within-run) and 93.0–110% (between-run). The criterion for precision was met for all analytes with coefficients of variation ≤ 6.1% (within-run) and ≤ 8.6% (between-run). No interferences from endogenous components of the matrix or carry-over effects were detected. The aglycones proved to be stable in plasma when stored for 24 h at room temperature and for 12 weeks at −20 °C or −80 °C. Samples can be frozen and thawed for a minimum of three cycles. The extracted and evaporated samples could be stored for 24 h at −20 °C. When stored in the autosampler, the extracted and re-dissolved samples were stable for at least 24 h at 4 °C. Stock solutions of the aglycone metabolites can be stored at room temperature for 24 h (see Supplementary Information S1 for detailed results of the method validation). Stability data for DOX and DOXol have been reported previously.\(^4,20\).

**Determination of degradation products in plasma.** The development of aglycones as products of degradation processes during long-term storage of DOX in plasma was investigated. Plasma was spiked with DOX at 25 µg L⁻¹ and 500 µg L⁻¹, respectively, and stored at 4 °C, −20 °C and −80 °C to reflect commonly used storage conditions. Three aliquots per concentration were immediately analysed for DOX and its metabolites and periodically within a period of about one year. In line with the EMA guideline quality control samples at three concentrations were analysed at the beginning and end of each analytical run.

**Determination of metabolites in clinical samples.** DOX, DOXol and the aglycone metabolites were analysed in a subset of 50 clinical samples from overall 44 paediatric cancer patients obtained within the pharmacokinetic phase-II EPOC-MS-001-Doxo trial (EudraCT number 2009-011454-17)\(^41\). Reanalysis of stored patient samples was approved by the competent local ethics committee (reference number 2016-154-f-S). Within the EPOC-MS-001-Doxo trial samples were analysed for DOX and DOXol. For reanalysis, samples were selected based on the original measurement results such that the whole concentration range of DOX was covered. To account for potentially short plasma half-lives of the aglycone metabolites, samples were selected that were taken either during DOX infusion or up to 4.25 h after the end of infusion to ensure detection of the metabolites. At the time of analysis the samples have already been stored for 6–8 years at −80 °C. As described above, quality controls where analysed with each analytical run.

**Ethics approval.** Clinical samples were obtained within the EPOC-MS-001-Doxo trial (EudraCT number 2009-011454-17). This trial did directly address the pharmacokinetics of Doxorubicin in children. The trial was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice Guidelines and applicable local regulatory requirements and laws. Written informed consent for participation in the EPOC-MS-001-Doxo trial including the analysis of Doxorubicin and metabolites was obtained from the patients’ parents or legal representatives. The use of stored clinical samples from the EPOC-MS-001-Doxo trial for the analyses described here was approved by the local ethics committee (ethics committee of the medical association Westfalen-Lippe and the University of Münster; reference number 2016-154-f-S).

**Results**

**Determination of degradation products in plasma.** Upon storage of spiked plasma samples at 4 °C DOX degraded almost completely within a few weeks (Fig. 2). After four weeks the DOX concentration relative to the initial concentration was 13.3% (25 µg L⁻¹) and 3.7% (500 µg L⁻¹), respectively. At −20 °C the concentration fell below 85% of the initial concentration after storage for four months. A reduction of the DOX concentration to 67.4% (25 µg L⁻¹) and 63.2% (500 µg L⁻¹) was observed after storage for about one year at −20 °C. When stored at −80 °C, DOX proved to be stable for at least one year (91.7% and 90.1%, respectively). The data on storage stability complement those reported previously.\(^4,20\). Though considerable degradation occurred both at 4 °C and −20 °C no concomitant increase in the concentration of any of the four aglycones was detected (Fig. 2).

**Determination of metabolites in clinical samples.** Although all four aglycone metabolites were detected in patient samples obtained from the EPOC-MS-001-Doxo trial, large differences exist regarding the proportion of samples in which each metabolite was detectable (see Fig. 3 for a representative chromatogram of a clinical sample). 7-Deoxydoxorubicinolone was the major aglycone metabolite and was quantified in 35 out of the 50 samples. In these samples the concentration of 7-deoxydoxorubicinolone ranged from 1.0 to 12.7 µg L⁻¹ (Fig. 4). In contrast, the aglycones doxorubicinone, doxorubicinolone and 7-deoxydoxorubicinone were only quantified in a few samples (doxorubicinone: 3/50 samples; doxorubicinolone: 9/50 samples; 7-deoxydoxorubicinone: 8/50 samples) and in very low concentrations (doxorubicinone: 1.0–2.1 µg L⁻¹; doxorubicinolone: 1.0–2.2 µg L⁻¹; 7-deoxydoxorubicinone: 1.0–2.6 µg L⁻¹) (Fig. 4). Overall, in 13/50 samples none of the four aglycones was quantified.

Until reanalysis, the samples from the EPOC-MS-001-Doxo trial have been stored for 6–8 years at −80 °C. Relevant degradation of DOX below 85% of the initially measured concentration value was observed in a subset of 14 samples which might have led to an increase in the concentration of aglycones. As indicated by the stability analysis described by Fig. 2, degradation of DOX during long-term storage does not lead to the formation of aglycones. Thus, aglycones quantified in the clinical samples can be considered to represent products of in vivo metabolism of DOX.

https://doi.org/10.1038/s41598-020-75662-w
Discussion
A point-of-care analytical platform for the detection of chemotherapeutics is currently under development within the DiaChemo project (https://www.diachemo.eu/). The technology is based on selective binding of drug
molecules by functionalised gold nanoparticles and separation of drug-bound nanoparticles via a liquid crystal matrix\textsuperscript{22,23}. Within the project DOX serves as a model substance. Various other non-chromatographic techniques have been employed for drug level analyses that are based on electrochemical or optical detection\textsuperscript{5–8}. Point-of-care analytics that minimise preanalytical variability and reduce technical effort will substantially facilitate drug monitoring. In the case of DOX, paediatric cancer patients might particularly benefit from point-of-care analytics which offer the possibility to improve dosing strategies and potentially increase the safety of DOX administration in this vulnerable patient population\textsuperscript{3}.

With regard to novel bioanalytical methods for DOX, pronounced plasma concentrations of the aglycones might interfere with the determination of DOX. Based on available data alone, the relevance of aglycones for DOX drug monitoring cannot be adequately defined. However, in our analysis the aglycones doxorubicinone, doxorubicinolone and 7-deoxydoxorubicinone were infrequently quantified in the samples from the EPOC-MS-001-Doxo trial and, if at all, in very low concentrations (doxorubicinone: 1.0–2.1 µg L\textsuperscript{-1}; doxorubicinolone: 1.0–2.2 µg L\textsuperscript{-1}; 7-deoxydoxorubicinone: 1.0–2.6 µg L\textsuperscript{-1}) (Fig. 4). From an analytical point of view, these metabolites are presumably of little significance. The situation might be different for 7-deoxydoxorubicinone which constituted the major aglycone metabolite in the clinical samples analysed here. Though the concentration of 7-deoxydoxorubicinone was low in most of the samples (1.0–12.7 µg L\textsuperscript{-1}), the relative content of this metabolite compared to the concentration of the parent drug DOX was 65% in one sample. Overall, in 5 out of the 35 samples in which 7-deoxydoxorubicinone could be quantified the concentration relative to DOX exceeded 10%. Potential analytical interference from this metabolite has therefore to be taken into account when developing a point-of-care device for the quantification of DOX.

It has to be underlined that the clinical samples analysed here have been stored for 6–8 years from sampling until reanalysis. The use of stored data raises two concerns. Firstly, relevant degradation of DOX was observed in 14 out of 50 samples and concomitant formation of aglycones might have been occurred during storage. However, we were not able to detect the formation of aglycones in plasma samples spiked with DOX when stored at 4 °C, − 20 °C or − 80 °C, though considerable degradation occurred at both 4 °C and − 20 °C (Fig. 2). This observation points to the formation of other decomposition products, possibly 6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione, which has been identified as a component in decomposition mixtures following degradation of DOX in aqueous solution\textsuperscript{24}. Of note, our results differ from stability data obtained upon short-term storage of DOX in plasma at 37 °C or room temperature which indicate that 7-deoxyaglycones might
be formed in consequence of the degradation of the parent drug molecule.\textsuperscript{11,25} The discrepancies between these results and ours may arise from both the differences in the storage period as well as in the storage conditions. Nevertheless, the limited storage stability of DOX need to be considered when reanalysing stored study samples e.g. when used as quality controls. Secondly, degradation of the aglycones themselves might have occurred during storage and hence the concentrations measured in the samples might be artificially low. Within validation of the HPLC method stability of the aglycones has only been proven for 3 months (see Supplementary Information S1). However, the results of our analysis are in accordance to those of previous studies which reported substantially low concentrations of the aglycone metabolites\textsuperscript{14–16}.

In contrast to the reports by Joerger et al. and Beijnen et al. who did not observe 7-deoxydoxorubicinolone,\textsuperscript{6,16} this metabolite constituted the major aglycone in the subset of patient samples from the EPOC-MS-001-Doxo trial. Discrepancies between studies in the type of aglycones observed in plasma might be attributed to potential differences in DOX metabolism, the quantification limit of the analytical method and the small number of patients included in the majority of studies. In our analysis, 7-deoxydoxorubicinolone could not be quantified in 15 out of 50 samples (30%) and in 14 of those 15 samples measurement values were between the detection limit and the quantification limit. Likewise, Cummings et al. reported 7-deoxyaglycones to be present in about 60% of patients.\textsuperscript{18} Hence, very low aglycone concentrations and small patient numbers hamper the detection of these metabolites. Exemplarily, only seven patients were included in the analysis by Joerger et al.\textsuperscript{15}

In conclusion, the data presented in this article confirm that aglycone metabolites are present in human plasma samples, but, with the exception of 7-deoxydoxorubicinolone, only very low concentrations were detected. Thus, our results support previous data that showed only low levels of the aglycones in plasma. In the subset of samples analysed, 7-deoxydoxorubicinolone was the major aglycone metabolite, which might be of relevance with regard to analytical interferences. Further, it seems to be unlikely that aglycones are formed as products of DOX degradation under storage conditions. The analyses underline the necessity to establish data on drug metabolites and degradation products and will help to avoid misinterpretation of doxorubicin drug monitoring results.

Data availability

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Received: 24 June 2020; Accepted: 14 October 2020
Published online: 29 October 2020

References

1. Heads of Medicines Agencies. Doxorubicinhydrochloride Teva 2 mg/ml solution for injection. Summary of Product Characteristics. Available at https://mri.cts-mrp.eu/Human/Product/Details/7875 (2009).
2. Feijen, E. A. M. L. et al. Risk and temporal changes of heart failure among 5-year childhood cancer survivors: A DCOG-LATER study. J. Am. Heart. Assoc. 8, e009122 (2019).
3. Siebel, C. et al. Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMJ Pharmacol. Toxicol. 21, 1–10 (2020).
4. Kontny, N. E., Hempel, G., Boos, J., Boddy, A. V. & Krischke, M. Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring—Using doxorubicin as an example. Ther. Drug. Monit. 33, 766–771 (2011).
5. Chandra, P., Zaidi, S. A., Noh, H.-B. & Shim, Y.-B. Separation and simultaneous detection of anticancer drugs in a microfluidic device with an amperometric biosensor. Biosens. Bioelectron. 28, 326–332 (2011).
6. Chekin, F. et al. Graphene-modified electrodes for sensing doxorubicin hydrochloride in human plasma. Anal. Bioanal. Chem. 411, 1509–1516 (2019).
7. Ferguson, B. S. et al. Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.3007095 (2013).
8. Liu, Y. & Danielsson, B. Rapid high throughput assay for fluorimetric detection of doxorubicin–application of nucleic acid-dye probe. Anal. Chim. Acta 587, 47–51 (2007).
9. Takanashi, S. & Bachur, N. R. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab. Dispos. 4, 79–87 (1976).
10. Kassner, N. et al. Carboxyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab. Dispos. 36, 2113–2120 (2008).
11. Andersen, A., Warren David, J. & Sørlad, L. A. Sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther. Drug. Monit. 15, 455–461 (1993).
12. Licata, S., Saponiero, A., Mordente, A. & Minotti, G. Doxorubicin metabolism and toxicity in human myocardium: Role of cytoplasmic deglycosidation and carbonyl reduction. Chem. Res. Toxicol. 13, 414–420 (2000).
13. Clementi, M. E., Giardina, B., Di Stasio, E., Mordente, A. & Misiti, F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 23, 2445–2450 (2003).
14. Andersen, A., Holte, H. & Sørlad, L. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother. Pharmacol. 44, 422–426 (1999).
15. Joerger, M., Huitema, A. D. R., Meenhorst, P. L., Schellens, J. H. M. & Beijnen, J. H. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother. Pharmacol. 55, 488–496 (2005).
16. Beijnen, J. H. et al. HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients. J. Pharm. Biomed. Anal. 9, 1005–1002 (1991).
17. Mross, K. et al. Pharmacokinetics and metabolism of epirubicin and doxorubicin in humans. J. Clin. Oncol. 6, 517–526 (1988).
18. Cummings, J., Mills, R., Cunningham, D. & Kaye, S. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: Evidence from metabolites identified in serum. Eur. J. Cancer Clin. Oncol. 22, 991–1001 (1986).
19. European Medicines Agency. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2*; Committee for Medicinal Products for Human Use (CHMP), 21 July 2011.
20. Maudens, K. E., Stove, C. P., Coeckx, V. F. J., Denys, H. & Lambert, W. E. Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva. J. Chromatogr. B 877, 3907–3915 (2009).
21. Krischke, M. et al. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial. Cancer Chemother. Pharmacol. 78, 1175–1184 (2016).
22. Serrano, L. A. et al. Phase behaviour and applications of a binary liquid mixture of methanol and a thermotropic liquid crystal. *Soft Matter* **14**, 4615–4620 (2018).

23. Fornerod, M. J., Amstad, E. & Guldin, S. Microfluidics of binary liquid mixtures with temperature-dependent miscibility. *Mol. Syst. Des. Eng.* **5**, 358–365 (2020).

24. Beijnen, J. H., van der Houwen, O. A. G. J. & Underberg, W. J. M. Aspects of the degradation kinetics of doxorubicin in aqueous solution. *Int. J. Pharm.* **32**, 123–131 (1986).

25. Maniez-Devos, D. M., Baurain, R., Lesne, M. & Trouet, A. Degradation of doxorubicin and daunorubicin in human and rabbit biological fluids. *J. Pharm. Biomed. Anal.* **4**, 353–365 (1986).

**Acknowledgements**

The authors wish to thank Petra Schulze Westhoff for excellent technical support. This research project received funding from the European Union’s research and innovation program Horizon 2020 under Grant Agreement No. 633635 (DIACHEMO).

**Author contributions**

All authors contributed to the conception of the study. C.S. performed HPLC analyses and drafted the manuscript. All authors commented on previous versions of the manuscript, read and approved the final version of the manuscript.

**Funding**

Open Access funding enabled and organized by Projekt DEAL.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-75662-w.

**Correspondence** and requests for materials should be addressed to J.B.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020